Q2 FY2026 EarningsQ2 FY26 missed consensus estimates across both top and bottom lines, with zero revenue reported against a $1.33M expectation. GAAP EPS of -$0.12 (calculated) was slightly below the -$0.1125 mean estimate. Despite the financial miss, the company secured $22.3M in gross proceeds through a public offering, extending its cash runway for at least one year and positioning for the commercial launch of preservative-free ketamine in 2026.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: NRX Therapeutics(NRXP) the Revenue is 1.101 M (--%), Miss estimate;the EBIT is -6.505 M (-74.4%), Miss estimate;the EPS is -0.44 (+55.1%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.00B--
0.00B--
-0.00B--%
EBITMiss expectations
-0.01B74.40%
-0.00B10.70%
-0.00B63.70%
EPSMiss expectations
-0.4455.10%
-0.112588.52%
-0.327533.42%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf